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Abstract
Objectives
Glycated haemoglobin A1c (HbA1c) measurement is recommended as an alternative to fast-
ing plasma glucose (FPG) for the diagnosis of pre-diabetes and type 2 diabetes. However,
evidence suggests discordance between HbA1c and FPG. In this study we examine a range
of metabolic risk features, pro-inflammatory cytokines, acute-phase response proteins,
coagulation factors and white blood cell counts to determine which assay more accurately
identifies individuals at increased cardiometabolic risk.
Materials and Methods
This was a cross-sectional study involving a random sample of 2,047 men and women
aged 46-73 years. Binary and multinomial logistic regression were employed to examine
risk feature associations with pre-diabetes [either HbA1c levels 5.7-6.4% (39-46 mmol/mol)
or impaired FPG levels 5.6-6.9 mmol/l] and type 2 diabetes [either HbA1c levels >6.5% (>48
mmol/mol) or FPG levels >7.0 mmol/l]. Receiver operating characteristic curve analysis
was used to evaluate the ability of HbA1c to discriminate pre-diabetes and diabetes defined
by FPG.
Results
Stronger associations with diabetes-related phenotypes were observed in pre-diabetic sub-
jects diagnosed by FPG compared to those detected by HbA1c. Individuals with type 2 dia-
betes exhibited cardiometabolic profiles that were broadly similar according to diagnosis by
either assay. Pre-diabetic participants classified by both assays displayed a more pro-
inflammatory, pro-atherogenic, hypertensive and insulin resistant profile. Odds ratios of
having three or more metabolic syndrome features were also noticeably increased (OR:
4.0, 95% CI: 2.8-5.8) when compared to subjects diagnosed by either HbA1c (OR: 1.4, 95%
CI: 1.2-1.8) or FPG (OR: 3.0, 95% CI: 1.7-5.1) separately.
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Conclusions
In middle-aged Caucasian-Europeans, HbA1c alone is a poor indicator of cardiometabolic
risk but is suitable for diagnosing diabetes. Combined use of HbA1c and FPG may be of
additional benefit for detecting individuals at highest odds of type 2 diabetes development.
Introduction
The prevalence of type 2 diabetes, a chronic disease which causes significant mortality, has
increased considerably in world populations, representing a major public health issue [1]. Dia-
betes is associated with a clustering of cardiometabolic features including obesity, dyslipidae-
mia, hypertension, insulin resistance, chronic low-grade inflammation [2, 3], and may lead to
severe cardiovascular complications [4].
Pre-diabetes, a condition defined by glycaemic profiles that are higher than normal but
which do not meet thresholds for diabetes, is a strong risk factor for type 2 diabetes and related
complications [5]. The American Diabetes Association (ADA) classifies type 2 diabetes as a
fasting plasma glucose (FPG) level7.0 mmol/l and pre-diabetes as impaired FPG levels
between 5.6–6.9 mmol/l [2]. In 2009 the International Expert Committee recommended gly-
cated haemoglobin A1c (HbA1c) as an alternative marker [6], and in 2010 the ADA introduced
HbA1c cut-points of6.5% (48 mmol/mol) for diabetes diagnosis and between 5.7–6.4%
(39–46 mmol/mol) as a criterion to identify individuals at a high-risk state of developing diabe-
tes [2]. Perceived benefits of the use of HbA1c measurement, over FPG, include greater pre-
analytical stability, lower biological variability and that the assay may be performed in non-
fasting blood samples [7, 8]. However, use of HbA1c as a screening tool has been controversial,
with research showing discordance between HbA1c and FPG [9–12], and several studies sug-
gesting that factors such as age or ethnicity may influence diagnostic performance [13–15].
The aim of this study was to compare the metabolic profiles in subjects with pre-diabetes
and type 2 diabetes, using ADA-recommended HbA1c and FPG diagnostic thresholds, in a ran-
dom sample of 2,047 middle-aged men and women. In particular, we examined a range of dia-
betes risk factors, metabolic syndrome (MetS) features, pro-inflammatory cytokines, acute-
phase response proteins, coagulation factors and white blood cell (WBC) counts to determine
which assay more accurately identifies individuals at increased cardiometabolic risk.
Materials and Methods
Study population
The Cork and Kerry Diabetes and Heart Disease Study (Phase II) was a single centre, cross-sec-
tional study conducted between 2010 and 2011. A random sample was recruited from a large
primary care centre in Mitchelstown, County Cork, Ireland. The Livinghealth Clinic serves a
population of approximately 20,000 Caucasian-European subjects, with a mix of urban and
rural residents. Stratified sampling was employed to recruit equal numbers of men and women
from all registered attending patients in the 46–73 year age group. In total, 3,807 potential par-
ticipants were selected from the practice list. Following the exclusion of duplicates, deaths, and
subjects incapable of consenting or attending appointment, 3,051 were invited to participate in
the study and of these, 2,047 (49.2% male) completed the questionnaire and physical examina-
tion components of the baseline assessment (response rate: 67.1%). The status of non-respond-
ers included individuals refusing to participate (59.4%) and those who did not reply (40.6%).
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Male subjects accounted for 53.7% of non-responders while 43.5% (vs. 42.8% of responders)
were>60 years of age. Details regarding the study design, sampling procedures and methods
of data collection have been reported previously [16].
Ethics committee approval conforming to the Declaration of Helsinki was obtained from
the Clinical Research Ethics Committee of University College Cork. A letter signed by the con-
tact GP in the clinic was sent out to all selected participants with a reply slip indicating accep-
tance or refusal. All subjects gave signed informed consent, including permission to use their
data for research purposes.
Clinical and laboratory procedures
All study participants attended the clinic in the morning after an overnight fast and blood sam-
ples were taken on arrival. Data on age, gender, family diabetes history, physician-diagnosed
type 2 diabetes and prescription (Rx) medication use were gathered through a self-completed
General Health Questionnaire. Triglyceride and high density lipoprotein cholesterol (HDL-C)
levels were measured by Cork University Hospital Biochemistry Laboratory on Olympus 5400
biochemistry analysers with Olympus reagents using standardised procedures and fresh sam-
ples (Olympus Diagnostica GmbH, Hamburg, Germany). Fasting glucose concentrations were
determined using a glucose hexokinase assay (Olympus Life and Material Science Europa Ltd.,
Lismeehan, Co. Clare, Ireland) and HbA1c levels were measured in the haematology laboratory
on an automated high-pressure liquid chromatography instrument Tosoh G7 [Tosoh HLC-
723 (G7), Tosoh Europe N.V, Tessenderlo, Belgium]. Serum insulin, c-reactive protein (CRP),
tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), adiponectin, leptin, resistin and
plasminogen activator inhibitor-1 (PAI-1) were assessed using a biochip array system (Evi-
dence Investigator; Randox Laboratories, UK). Complement component 3 (C3) was measured
by immunoturbidimetric assay (RX Daytona; Randox Laboratories). White blood cell counts
were determined by flow cytometry technology as part of a full blood count.
Three independent measurements of systolic and diastolic blood pressure (BP) were
obtained with the subject in a seated position using an Omron M7 digital sphygmomanometer
(Omron Healthcare Co. Ltd., Japan). The mean of the second and third readings was consid-
ered to be a subject’s BP. The weight and height of each participant were measured to the near-
est 0.1 kg and 0.1 cm respectively. Portable electronic Tanita WB-100MA weighing scales
(Tanita Corporation, IL, USA) were placed on a firm, flat surface and were calibrated weekly to
ensure accuracy. Height was measured using a portable Seca Leicester height/length stadi-
ometer (Seca, Birmingham, UK) and body mass index (BMI) was calculated as weight divided
by the square of height. A BMI30 kg/m2 was classified as obese. Waist circumference (WC)
was measured between the lowest rib and iliac crest on bare skin. Subjects were instructed to
breathe in, and then out, and to hold their breath while measurement was made to the nearest
0.1 cm using a Seca 200 measuring tape. Two independent measurements of WC were taken
and the mean of the two was used in analysis. Central obesity was defined as a WC level102
cm for males and88 cm for females.
Classification of biochemical and blood pressure measurements
Lipid, lipoprotein and BP measurements were categorised according to National Cholesterol
Education Program Adult Treatment Panel III (NCEP: ATP III) guidelines [17]. Abnormal
metabolic risks were defined as high triglycerides1.7 mmol/l and low HDL-C (<1.03 mmol/l
in males or<1.29 mmol/l in females). Dyslipidaemia was determined according to both high
triglyceride and low HDL-C levels. Elevated BP was classified as systolic BP130 mmHg and/
or diastolic BP85 mmHg or Rx anti-hypertensive medication use. High serum insulin was
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defined as a level equal to or above the 75th percentile in the study sample. Metabolic syndrome
was determined according to a modified version of the NCEP: ATP III criterion, substituting
serum insulin 75th percentile for impaired FPG. Three or more MetS features (3 MetS) was
characterised as any combination of the following: obesity defined by WC, high triglyceride
levels, low HDL-C, elevated BP and high insulin concentrations. According to ADA guidelines,
pre-diabetes was classified as elevated HbA1c levels between 5.7–6.4% (39–46 mmol/mol) or
impaired FPG levels between 5.6–6.9 mmol/l. Type 2 diabetes was defined as HbA1c6.5%
(48 mmol/mol) or FPG7.0 mmol/l [2]. As internationally recognised risk cut-points for
the examined biomarkers have not been established, we classified inflammation and raised
immune activation as a level above the study population median for each biomarker (C3, CRP,
IL-6, TNF-α, leptin, resistin, PAI-1 andWBC) with the exception of adiponectin (below
median level).
Statistical analysis
Descriptive characteristics were examined according to diagnosis of pre-diabetes and type 2
diabetes. Categorical features are presented as percentages and continuous variables are dis-
played as a mean (plus or minus one standard deviation) or a median and interquartile range
for skewed data. Binary logistic regression was used to explore diabetes-related risk factor and
inflammatory biomarker relationships with pre-diabetes (compared to normoglycaemic sub-
jects) and type 2 diabetes (compared to individuals without diabetes) defined using HbA1c and
FPG diagnostic cut-points. Models examining metabolic feature associations with pre-diabetes
excluded patients with type 2 diabetes indicated by either HbA1c or FPG, a physician diagnosis
or Rx diabetes medication use. Risk feature relationships with pre-diabetes (either HbA1c
alone, FPG alone or dual categorisation by both HbA1c and FPG) were further evaluated using
multinomial logistic regression. Subjects classified as normoglycaemic by both assays were
used as the reference category.
The ability of HbA1c to discriminate pre-diabetes (defined by impaired FPG) and type 2 dia-
betes (defined by FPG levels7.0 mmol/l) was assessed using receiver operating characteristic
curve (ROC) analysis. The area under the curve (AUC) provides a scale from 0.5 to 1.0 (with
0.5 representing random chance and 1.0 indicating perfect discrimination) by which to com-
pare the ability of a marker to detect a positive result [18]. The diagnostic properties of differ-
ent HbA1c thresholds were contrasted by determining sensitivity and false positive rates (FPR).
Levels of agreement between diagnostic methods were ascertained using Cohen’s kappa coeffi-
cient (K).
Primary data analysis was conducted using IBM SPSS Statistics Version 20 (IBM Corp.,
Armonk, NY, USA) for Windows. Confidence intervals for prevalence proportions were calcu-
lated using the VasserStats statistical website [19]. For all analyses, a P value (two-tailed) of less
than 0.05 was considered to indicate statistical significance. Assay results for HbA1c and FPG
were available for 1,995 (97.5%) and 1,994 (97.4%) subjects. Participants missing either HbA1c
or FPG data were excluded from multinomial and ROC analyses. Low-level missing values
were found within most independent variables. Sensitivity analysis indicated a similar percent-
age of missing data according to either HbA1c or FPG pre-diabetes and diabetes classifications.
Missing independent variable data were thus assumed to be ignorable and missing at random.
Results
Descriptive characteristics
Characteristics of the study population according to pre-diabetes and type 2 diabetes classifica-
tions are presented in Table 1. The prevalence of pre-diabetes was 49.1% (95% CI: 46.9%-
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Table 1. Characteristics of the study population according to pre-diabetes and type 2 diabetes status.
Feature Full cohort Pre-diabetes1 Type 2 diabetes2
HbA1c FPG HbA1c FPG
(N = 2047) (N = 980) (N = 230) (N = 146) (N = 85)
Male 1008 (49.2) 441 (45.0) 150 (65.2) 95 (65.1) 59 (69.4)
Age 59.0 (55.0–64.0) 60.0 (55.0–64.0) 61.0 (56.0–65.0) 60.0 (57.0–65.0) 61.0 (56.5–64.5)
Age 60 981 (47.9) 510 (52.0) 125 (54.3) 83 (56.8) 51 (60.0)
Diagnosed diabetes 101 (4.9) - - 73 (50.0) 51 (60.0)
On Rx for diabetes 78 (3.8) - - 60 (41.1) 41 (48.2)
On Rx for hypertension 584 (28.5) 307 (31.3) 98 (42.6) 81 (55.5) 48 (56.5)
On Rx for cholesterol 711 (34.7) 385 (39.3) 93 (40.4) 88 (60.3) 49 (57.6)
BMI (kg/m2) 28.60 ± 4.7 28.80 ± 4.7 30.45 ± 5.2 32.17 ± 5.5 31.81 ± 5.5
BMI 30 668 (32.7) 345 (35.2) 109 (47.4) 85 (58.2) 49 (57.6)
WC (cm) 97.04 ± 13.2 97.08 ± 12.9 102.44 ± 12.8 107.91 ± 13.7 108.52 ± 13.9
WC (HIGH) 1119 (54.8) 562 (57.4) 150 (65.2) 119 (81.5) 66 (77.6)
Family diabetes history 390 (19.1) 176 (18.0) 46 (20.0) 62 (42.5) 41 (48.2)
Triglycerides (mmol/l) 1.22 (0.9–1.7) 1.23 (0.9–1.7) 1.41 (1.0–2.0) 1.58 (1.2–2.3) 1.68 (1.2–2.3)
Triglycerides 1.7 490 (24.6) 230 (23.8) 85 (37.9) 65 (45.5) 40 (48.8)
HDL-C (mmol/l) 1.45 ± 0.4 1.45 ± 0.4 1.32 ± 0.3 1.17 ± 0.3 1.17 ± 0.4
HDL-C (LOW) 353 (17.6) 165 (17.0) 59 (26.1) 66 (45.2) 35 (41.2)
Dyslipidaemia 168 (8.4) 78 (8.0) 32 (14.0) 37 (25.3) 22 (25.9)
Systolic BP (mmHg) 129.60 ± 16.8 130.10 ± 16.1 134.78 ± 15.5 134.19 ± 17.3 136.24 ± 17.4
Diastolic BP (mmHg) 80.12 ± 9.7 80.24 ± 9.6 82.25 ± 9.1 79.50 ± 10.3 80.72 ± 10.5
BP 130/85 1045 (51.3) 521 (53.4) 155 (67.7) 89 (61.4) 56 (66.7)
HbA1c (%) 5.7 (5.5–6.0) 5.9 (5.7–6.0) 5.8 (5.6–6.1) 7.0 (6.7–8.1) 7.6 (6.8–9.0)
HbA1c (mmol/mol) 39 (37–42) 41 (39–42) 40 (38–43) 53 (50–65) 60 (51–75)
FPG (mmol/l) 4.90 (4.7–5.4) 5.00 (4.7–5.3) 5.80 (5.7–6.1) 6.90 (6.0–9.0) 8.50 (7.6–10.8)
Insulin (μU/ml) 8.65 (5.3–14.1) 8.98 (4.6–11.8) 12.67 (7.4–19.5) 18.27 (10.6–31.9) 19.21 (12.1–30.9)
Insulin 75th percentile 497 (25.0) 238 (24.6) 98 (43.2) 94 (65.7) 59 (70.2)
3 MetS features3 606 (29.6) 298 (30.4) 112 (48.7) 103 (70.5) 63 (74.1)
C3 (mg/dl) 135.92 ± 24.7 138.85 ± 24.5 141.41 ± 25.8 148.13 ± 28.6 149.20 ± 24.9
CRP (ng/ml) 1.35 (1.0–2.3) 1.43 (1.0–2.4) 1.38 (1.0–2.3) 1.79 (1.1–3.2) 1.91 (1.2–3.0)
IL-6 (pg/ml) 1.81 (1.2–2.9) 1.91 (1.3–3.0) 2.02 (1.5–3.0) 2.92 (1.7–4.8) 2.83 (1.8–4.6)
TNF-α (pg/ml) 5.97 (4.9–7.3) 6.02 (5.0–7.3) 5.94 (4.9–7.5) 6.99 (5.5–8.3) 7.09 (5.6–8.1)
Adiponectin (ng/ml) 4.75 (2.9–7.5) 4.92 (3.1–7.5) 3.63 (2.4–5.6) 2.82 (1.7–4.6) 2.73 (1.9–4.7)
Leptin (ng/ml) 1.95 (1.1–3.1) 2.09 (1.3–3.5) 2.06 (1.3–3.8) 2.28 (1.3–3.9) 2.09 (1.1–3.4)
Resistin (ng/ml) 5.07 (3.9–6.7) 4.93 (3.8–6.6) 4.89 (3.7–6.7) 6.15 (4.6–7.3) 5.53 (4.5–7.3)
PAI-1 (ng/ml) 27.38 ± 12.6 27.87 ± 12.0 29.56 ± 13.2 31.35 ± 15.9 30.03 ± 11.0
WBC (109/l) 6.00 ± 1.9 6.12 ± 2.1 6.33 ± 1.72 7.39 ± 2.4 7.21 ± 1.9
Mean and ± standard deviation are shown for continuous variables. Age, triglycerides, HbA1c, FPG, insulin, CRP, IL-6, TNF-α, adiponectin, leptin and
resistin are shown as a median (interquartile range). Numbers and % (in brackets) for categorical variables will vary in different analyses as some
variables have missing values.
1Pre-diabetes: HbA1c levels 5.7–6.4% (39–46 mmol/mol) or FPG levels 5.6–6.9 mmol/l.
2Type 2 diabetes: HbA1c 6.5% (48 mmol/mol) or FPG 7.0 mmol/l.
3MetS features: WC (HIGH), triglycerides 1.7, HDL-C (LOW), BP 130/85 or Rx and insulin 75th percentile.
doi:10.1371/journal.pone.0134154.t001
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51.3%) by elevated HbA1c and 11.5% (95% CI: 10.2%-13.0%) by impaired FPG. Subjects cate-
gorised as pre-diabetic using HbA1c had lower BMI and WC levels, lower triglyceride and insu-
lin concentrations, higher HDL-C levels, were less hypertensive, and a greater proportion were
female when compared to individuals with pre-diabetes defined by FPG.
Logistic regression
In binary logistic regression analyses (Table 2), associations between commonly assessed diabe-
tes risk factors and pre-diabetes were stronger in subjects diagnosed by FPG. Odds ratios for
pre-diabetes indicated by HbA1c were non-significant for having a family diabetes history and
elevated triglyceride levels, while there was a three-fold increased likelihood (OR: 3.0, 95% CI:
2.2–3.9) of having3 MetS features in participants identified by FPG compared to an odds
ratio of 1.6 (95% CI: 1.3–2.0) in pre-diabetes by HbA1c. In contrast, metabolic risk factor rela-
tionships with type 2 diabetes were generally comparable according to diagnosis by either
assay, with odds ratios of having3 MetS features being 6.1 (95% CI: 4.2–8.8) and 6.8 (95%
CI: 4.1–11.2) for subjects diagnosed by HbA1c and FPG respectively. Regardless of definition,
Table 2. Odds ratios (95% CI) of having risk factors according to diagnosis of pre-diabetes and type 2 diabetes by HbA1c or FPG.
Feature Odds ratios (95% CI)1
Pre-diabetes compared to normoglycaemia2 Type 2 diabetes compared to no diabetes3
HbA1c P value FPG P value HbA1c P value FPG P value
Male 0.8 (0.6–0.9) <0.001 2.3 (1.7–3.0) <0.001 2.0 (1.4–2.9) <0.001 2.5 (1.5–3.9) <0.001
Age 60 1.6 (1.3–1.9) <0.001 1.4 (1.1–1.9) 0.011 1.5 (1.1–2.2) 0.018 1.7 (1.1–2.7) 0.017
Family diabetes history 1.2 (0.9–1.5) 0.182 1.4 (1.0–2.1) 0.043 4.1 (2.9–5.9) <0.001 5.2 (3.3–8.1) <0.001
BMI 30 1.8 (1.4–2.2) <0.001 2.2 (1.7–3.0) <0.001 3.1 (2.2–4.3) <0.001 2.8 (1.8–4.4) <0.001
WC (HIGH) 1.5 (1.2–1.9) 0.001 2.0 (1.4–3.1) 0.001 5.4 (2.5–11.8) <0.001 7.4 (2.3–23.5) 0.001
Triglycerides 1.7 1.2 (0.9–1.5) 0.134 2.1 (1.5–2.8) <0.001 2.5 (1.8–3.6) <0.001 2.8 (1.8–4.4) <0.001
HDL-C (LOW) 1.4 (1.1–1.8) 0.018 2.3 (1.7–3.3) <0.001 4.6 (3.2–6.6) <0.001 3.6 (2.3–5.7) <0.001
Dyslipidaemia 1.6 (1.1–2.4) 0.019 2.6 (1.7–4.1) <0.001 4.3 (2.8–6.5) <0.001 4.1 (2.4–6.9) <0.001
BP 130/85 or Rx 1.4 (1.2–1.7) <0.001 2.5 (1.8–3.5) <0.001 3.0 (1.9–4.8) <0.001 4.4 (2.2–8.6) <0.001
Insulin 75th percentile 1.6 (1.3–2.0) <0.001 3.1 (2.3–4.2) <0.001 6.5 (4.5–9.4) <0.001 7.2 (4.4–11.7) <0.001
3 MetS features4 1.6 (1.3–2.0) <0.001 3.0 (2.2–3.9) <0.001 6.1 (4.2–8.8) <0.001 6.8 (4.1–11.2) <0.001
C35 1.8 (1.5–2.2) <0.001 1.4 (1.0–1.8) 0.032 3.3 (2.2–4.9) <0.001 3.1 (1.9–5.0) <0.001
CRP5 1.4 (1.1–1.7) 0.001 1.2 (0.9–1.5) 0.293 1.5 (1.1–2.2) 0.02 1.6 (1.0–2.6) 0.032
IL-65 1.6 (1.3–1.9) <0.001 1.5 (1.1–2.0) 0.005 2.8 (1.9–4.1) <0.001 2.8 (1.7–4.6) <0.001
TNF-α5 1.2 (1.0–1.4) 0.078 1.0 (0.7–1.3) 0.738 2.3 (1.6–3.3) <0.001 2.7 (1.6–4.4) <0.001
Adiponectin5 1.4 (1.1–1.7) 0.004 2.0 (1.4–2.7) <0.001 4.0 (2.5–6.2) <0.001 3.2 (1.8–5.6) <0.001
Leptin5 1.5 (1.2–1.8) <0.001 1.4 (1.1–1.9) 0.014 1.5 (1.0–2.1) 0.026 1.2 (0.8–1.8) 0.48
Resistin5 0.9 (0.8–1.1) 0.305 0.9 (0.7–1.2) 0.391 2.4 (1.7–3.5) <0.001 1.8 (1.1–2.8) 0.012
PAI-15 1.3 (1.1–1.6) 0.005 1.3 (1.0–1.7) 0.108 1.5 (1.0–2.1) 0.028 1.5 (1.0–2.4) 0.078
WBC5 1.7 (1.4–2.1) <0.001 1.6 (1.2–2.1) 0.001 3.4 (2.3–5.0) <0.001 3.3 (2.0–5.5) <0.001
1Binary logistic regression. Gender adjusted for age (continuous), age 60 adjusted for gender, all other variables adjusted for age (continuous) and
gender.
2Pre-diabetes: HbA1c 5.7% (39 mmol/mol) or FPG 5.6 mmol/l, models exclude subjects with type 2 diabetes: HbA1c 6.5% (48 mmol/mol) or FPG
7.0 mmol/l or physician diagnosis or Rx diabetes medication use.
3Models exclude 24 subjects that indicated a physician diagnosis or Rx diabetes medication use but who did not have positive HbA1c or FPG test results.
4MetS features: WC (HIGH), triglycerides 1.7, HDL-C (LOW), BP 130/85 or Rx and insulin 75th percentile.
5Threshold: above median level in the study population except adiponectin (below median level).
doi:10.1371/journal.pone.0134154.t002
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patients with pre-diabetes and type 2 diabetes displayed a chronic pro-inflammatory profile as
characterised by elevated C3, IL-6, WBC levels and reduced adiponectin concentrations.
The results from multinomial regression models exploring risk factor relationships with
pre-diabetes classified by HbA1c alone, FPG alone, or by both HbA1c and FPG together are dis-
played in Table 3. Odds ratios for obesity, elevated BP, increased insulin concentrations and
MetS were higher in participants classified by both assays, with four-fold increased odds (OR:
4.0, 95% CI: 2.8–5.8) of having3 MetS features, compared to either HbA1c (OR: 1.4, 95% CI:
1.2–1.8) or FPG (OR: 3.0, 95% CI: 1.7–5.1) alone. Stronger associations with markers of inflam-
mation were also observed in subjects identified by both criteria.
ROC analysis
Receiver operating characteristic curves for HbA1c to detect pre-diabetes and type 2 diabetes
are shown in Figs 1 and 2. The ability of HbA1c to discriminate pre-diabetes characterised by
impaired FPG was low (AUC: 0.668, 95% CI: 0.627–0.710). The HbA1c5.7% (39 mmol/
mol) pre-diabetes threshold demonstrated marginal sensitivity (72%) and a high FPR (52%).
Table 3. Odds ratios (95% CI) of having risk factors according to diagnosis of pre-diabetes1 by HbA1c alone, FPG alone, or by both HbA1c and FPG
together.
Feature Odds ratios (95% CI)2
HbA1c alone P value FPG alone P value HbA1c & FPG P value
(N = 814) (N = 62) (N = 162)
Male 0.8 (0.6–0.9) 0.006 3.3 (1.8–5.9) <0.001 1.6 (1.2–2.3) 0.005
Age 60 1.6 (1.3–1.9) <0.001 1.4 (0.8–2.3) 0.251 2.0 (1.4–2.8) <0.001
Family diabetes history 1.1 (0.8–1.4) 0.474 1.2 (0.6–2.4) 0.651 1.7 (1.1–2.6) 0.013
BMI 30 1.6 (1.3–2.0) <0.001 1.7 (1.0–3.0) 0.051 3.4 (2.4–4.9) <0.001
WC (HIGH) 1.4 (1.2–1.8) <0.001 2.0 (1.2–3.4) 0.011 2.6 (1.8–3.7) <0.001
Triglycerides 1.7 1.2 (0.9–1.5) 0.267 2.5 (1.4–4.3) 0.001 2.3 (1.4–4.3) <0.001
HDL-C (LOW) 1.3 (1.0–1.7) 0.095 2.5 (1.3–4.7) 0.004 2.8 (1.8–4.3) <0.001
Dyslipidaemia 1.6 (1.0–2.5) 0.041 3.5 (1.6–7.8) 0.002 3.5 (2.0–6.2) <0.001
BP 130/85 or Rx 1.3 (1.0–1.6) 0.012 2.2 (1.2–3.9) 0.009 3.3 (2.2–5.1) <0.001
Insulin 75th percentile 1.5 (1.2–2.0) 0.002 3.4 (2.0–5.9) <0.001 4.1 (2.8–5.9) <0.001
3 MetS features3 1.4 (1.2–1.8) 0.003 3.0 (1.7–5.1) <0.001 4.0 (2.8–5.8) <0.001
C34 1.8 (1.5–2.3) <0.001 1.4 (0.9–2.4) 0.17 2.2 (1.5–3.1) <0.001
CRP4 1.4 (1.1–1.7) 0.002 1.1 (0.7–2.0) 0.640 1.5 (1.1–2.2) 0.017
IL-64 1.5 (1.2–1.9) <0.001 1.4 (0.8–2.4) 0.212 2.1 (1.5–3.0) <0.001
TNF-α4 1.2 (1.0–1.5) 0.096 0.8 (0.5–1.4) 0.524 1.1 (0.8–1.6) 0.446
Adiponectin4 1.3 (1.0–1.6) 0.043 1.3 (0.7–2.3) 0.373 2.6 (1.8–3.9) <0.001
Leptin4 1.4 (1.2–1.8) <0.001 1.3 (0.8–2.2) 0.345 2.0 (1.4–2.9) <0.001
Resistin4 1.0 (0.8–1.2) 0.626 1.3 (0.7–2.1) 0.389 0.8 (0.5–1.1) 0.139
PAI-14 1.3 (1.1–1.6) 0.008 1.4 (0.8–2.4) 0.2 1.6 (1.1–2.2) 0.014
WBC4 1.6 (1.3–2.0) <0.001 1.3 (0.7–2.2) 0.371 2.6 (1.8–3.7) <0.001
1Pre-diabetes: HbA1c 5.7% (39 mmol/mol) or FPG 5.6 mmol/l, models exclude subjects with type 2 diabetes: HbA1c 6.5% (48 mmol/mol) or FPG
7.0 mmol/l or physician diagnosis or Rx diabetes medication use.
2Multinomial logistic regression, reference category: normoglycaemia by both HbA1c and FPG. Gender adjusted for age (continuous), age 60 adjusted
for gender, all other variables adjusted for age (continuous) and gender.
3MetS features: WC (HIGH), triglycerides 1.7, HDL-C (LOW), BP 130/85 or Rx and insulin 75th percentile.
4Threshold: above median level in the study population except adiponectin (below median level).
doi:10.1371/journal.pone.0134154.t003
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The level of agreement between both diagnostic methods was also poor (K: 0.084). Discrimina-
tory capacity for type 2 diabetes defined by FPG7.0 mmol/l was high (AUC: 0.941, 95% CI:
0.902–0.980). Sensitivity, FPR and kappa for the ADA-recommended HbA1c6.5% (48
mmol/mol) cut-off were 84%, 4% and 0.60 respectively.
Fig 1. Receiver operating characteristic curve for HbA1c to discriminate subjects with pre-diabetes.
The figure shows an ROC curve for HbA1c (continuous) to discriminate subjects with pre-diabetes (impaired
FPG5.6 mmol/l). The area under the curve value was AUC: 0.668, (95% CI: 0.627–0.710).
doi:10.1371/journal.pone.0134154.g001
Fig 2. Receiver operating characteristic curve for HbA1c to discriminate subjects with type 2 diabetes.
The figure shows an ROC curve for HbA1c (continuous) to discriminate subjects with type 2 diabetes (FPG
7.0 mmol/l). The area under the curve value was AUC: 0.941, (95%CI: 0.902–0.980).
doi:10.1371/journal.pone.0134154.g002
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Discussion
In this study of 2,047 middle-aged Caucasian-European men and women we show that subjects
with HbA1c levels 5.7–6.4% (39–46 mmol/mol) or FPG levels 5.6–6.9 mmol/l may exhibit dif-
ferent cardiometabolic profiles. Stronger relationships with diabetes-related risk features were
found using impaired FPG compared to elevated HbA1c to diagnose pre-diabetes. Conversely,
the metabolic profiles of patients with type 2 diabetes, defined by either HbA1c6.5% (48
mmol/mol) or FPG7.0 mmol/l concentrations, were broadly similar. In addition, it was
noted that associations with risk factors and inflammatory markers were higher in pre-diabetic
individuals classified by both assays. These results suggest that a combination of both criteria
may be useful for detecting subjects at increased cardiometabolic risk.
Noticeably, within this population, a higher percentage of patients were identified as having
pre-diabetes by HbA1c (49.1% vs. 11.5% for FPG). A higher prevalence of pre-diabetes by
HbA1c in a United Kingdom cohort (N = 8,696) was also noted by Mostafa et al. [20], who
reported a prevalence of 44.9% in participants diagnosed by HbA1c compared to 16.2% in sub-
jects detected by an oral glucose tolerance test (OGTT). Similar findings were determined
using FPG as the glucose-based criterion. Our results are also consistent with those reported in
a recent Chinese study (N = 2,318) and from research examining a Palestinian Arab population
(N = 1,370). Du et al. [21] and Kharroubi et al. [22] found reasonable or moderate concordance
between HbA1c and FPG for type 2 diabetes, but a higher prevalence by HbA1c and limited
overlap for pre-diabetes using ADA-designated thresholds.
However, our results contrast with findings reported in the United States by the Insulin
Resistance Atherosclerosis Study (N = 855), which found a higher prevalence of pre-diabetes
by FPG (31.1% vs. 10.6% for HbA1c) [23]. Similarly, research utilising data from the National
Health and Nutrition Examination Survey (1999–2006) found the prevalence of pre-diabetes
in a sample of 7,029 adults to be 28.2% and 12.6% using FPG and HbA1c respectively [24]. Pos-
sible reasons for observed prevalence disparities between HbA1c and FPG may include age,
gender or ethnic differences in examined populations [10, 14, 15]. In addition, as glucose con-
tinues to be metabolized in blood cells even after sampling, discrepancies may be due to bio-
chemical analysis intervals within different studies [7, 22].
Longitudinal research has suggested that combined use of HbA1c and FPG may be beneficial
for identifying high-risk subjects. In two Asian studies, Inoue et al. [25] and Heianza et al. [26]
demonstrated hazard ratios for type 2 diabetes to be greater for subjects classified by both
assays when compared to those diagnosed by either HbA1c or FPG separately. Findings from
the Kansai Healthcare Study showed that joint use of both methods improved predictive ability
[27]. In ROC analysis, AUCs for models including both HbA1c and FPG were larger than those
for HbA1c (0.853 vs. 0.771; P<0.001) or FPG (0.853 vs. 0.818; P<0.001) alone. Recent research
by Lipska et al. also revealed that addition of HbA1c to a model with impaired FPG improved
discrimination and calibration [28]. The results from the present study imply that the mecha-
nism for this association is that individuals with diabetes-related phenotypes are more accu-
rately identified using combined criteria.
Established risk factors for type 2 diabetes include obesity, raised triglyceride and low
HDL-C levels, hypertension and insulin resistance [29]. In particular, subjects with a combina-
tion of these features have been shown to have a five-fold increased risk of developing diabetes
[30]. Cardiovascular diseases, and in particular obesity-related type 2 diabetes, are also charac-
terised by a low-grade but chronic inflammatory state [31, 32]. This may be reflected in an
increased production of pro-inflammatory cytokines and also in higher levels of acute-phase
response proteins, coagulation factors, macrophages and immune cells and lower levels of adi-
ponectin, the anti-inflammatory adipokine [32, 33].
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In our study it was noted that pre-diabetic individuals categorised by both assays demon-
strated a stronger association with cardiometabolic feature clustering and displayed a more
pro-inflammatory, pro-atherogenic, hypertensive and insulin resistant profile. Though few
prospective studies have comprehensively identified features related to pre-diabetes develop-
ment, it has been suggested that risk factors for pre-diabetes mirror those for type 2 diabetes
[34]. Consequently, on the basis of the similar risk profiles noted in this study between pre-dia-
betes (defined using both HbA1c and FPG) and type 2 diabetes (classified by either method),
these findings also indicate that combined use of both assays may be clinically useful for detect-
ing individuals at highest odds of developing diabetes.
Although HbA1c has long been used as a marker for glycaemic control, its diagnostic perfor-
mance for type 2 diabetes is still questioned [35–37]. Though a more expensive assay, when
compared with FPG, HbA1c has advantages including convenience, greater pre-analytical sta-
bility, lower biological variability and increasing international standardisation [7, 37]. More-
over, HbA1c has been shown to correlate with cardiovascular disease and all-cause mortality
[38]. However, as diabetes is clinically defined by elevated blood glucose, and not by glycation
of proteins, there is concern that using HbA1c to classify type 2 diabetes may lead to major
changes in the pathophysiological paradigm that defines the condition [7]. Although a report
from the United States inferred that diagnosis by HbA1c, rather than FPG, would not signifi-
cantly alter type 2 diabetes prevalence, and that categorisation would remain unchanged in as
many as 97.7% of subjects [39], evidence is still equivocal [40].
Notably, within our sample, a higher prevalence of diabetes was determined using HbA1c
(7.3%, 95% CI: 6.3%-8.6%) compared to FPG (4.3%, 95% CI: 3.5%-5.2%). However, a similar
type 2 diabetes prevalence rate in middle-aged Irish adults, defined by HbA1c, was recently
reported using data from the nationally representative 2007 Survey of Lifestyle, Attitudes and
Nutrition (7.1%, 95% CI: 5.2%-9.0%) [40, 41]. It was also noted that diabetic subjects identified
by HbA1c or FPG within the present study displayed markedly similar cardiometabolic profiles.
In addition, HbA1c demonstrated high predictive ability for type 2 diabetes diagnosed by FPG
7.0 mmol/l levels. Conversely, HbA1c showed poor discriminatory capacity for pre-diabetes
defined by impaired FPG.
As HbA1c reflects long-term glycaemic exposure, including postprandial glucose spikes,
rather than the acute dysglycaemia indicated by FPG, it is rational to assume that each assay
may identify different individuals. Our results suggest that HbA1c may provide greater sensitiv-
ity for diagnosing type 2 diabetes within this sample. However, the limited overlap and sub-
stantially varied cardiometabolic profiles in subjects diagnosed with pre-diabetes, by either
HbA1c or FPG, imply that HbA1c alone may lack specificity to accurately detect individuals at
risk of diabetes development. It was also noted that metabolic risk profiles in pre-diabetic sub-
jects, classified by impaired FPG levels only, were also considerably increased. This indicates
that a percentage of high-risk individuals would be missed if HbA1c was employed as a sole
diagnostic criterion.
This study has several strengths, including a high participation rate (67%). As far as we are
aware, ours is the first to compare pre-diabetes and type 2 diabetes prevalence, defined using
both HbA1c and FPG criteria, in a middle-aged Irish population. Additionally, few studies have
compared a broad range of metabolic risk features and biomarkers with pre-diabetes and type
2 diabetes diagnosed by both assays. Our results are of potential clinical significance in terms of
screening and the use of HbA1c as a method for diagnosing diabetes and determining cardio-
metabolic risk. Accurate estimates of progression rates to type 2 diabetes are needed for effi-
cient allocation of resources and to optimise public health prevention strategies [42].
Importantly, our findings indicate that caution should be taken with regard to how risk is
defined as inexact methods may overestimate future diabetes burden [43, 44].
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Notwithstanding these strengths, several limitations can be identified. These include single
measurements of HbA1c and FPG and that we did not have OGTT results as a comparison test.
Although use of a third assay would have allowed a more thorough evaluation of HbA1c and
FPG, as discussed by Bonora et al. [7] comparisons between diagnostic methods for pre-diabe-
tes and type 2 diabetes are ambiguous, as a true gold standard test is unavailable. Also, cross-
sectional data precludes examination of temporal relationships. Consequently, though results
from our research suggest associations between variables, they do not demonstrate an ability to
predict type 2 diabetes or future cardiovascular events.
Equally of concern is that our data were derived from a single primary care based sample.
Although results from the Cork and Kerry Diabetes and Heart Disease Study demonstrate
prevalence rates for obesity and cardiovascular outcomes similar to those observed in other
nationally representative Irish studies [40, 41, 45], the possibility that this sample is not repre-
sentative of the source population must be acknowledged. However, previous research suggests
that approximately 98% of Irish adults are registered with a GP and that, even in the absence of
a universal patient registration system, it is possible to perform population-based epidemiolog-
ical studies that are representative using these methods [46]. In addition, Ireland presents a
generally ethnically homogeneous population [47]. Thus, the associations we observed between
cardiometabolic features and HbA1c and FPG may be comparable to other middle-aged Irish
adults. As random sampling of subjects and the use of validated methods for data collection
ensured internal sample validity, it is equally possible that the relationships described may be
generalisable to a similar middle-aged, Caucasian-European population. Nevertheless, future
studies utilising longitudinal data in different samples will be needed to confirm these findings.
In particular, it will be necessary to determine whether risk stratification, using both assays, is
clinically useful as a method for predicting type 2 diabetes.
Conclusions
In summary, our results suggest that in middle-aged Caucasian-Europeans, when using ADA-
recommended cut-points, HbA1c alone is a poor indicator of diabetes risk, but is appropriate
for type 2 diabetes diagnosis. Furthermore, combined use of HbA1c and FPG identifies subjects
at substantially increased cardiometabolic risk. Although the efficacy and cost-effectiveness of
routine screening for diabetes in primary care has not been established [48–50], in light of the
increasing prevalence of type 2 diabetes worldwide, there is a need to identify high-risk sub-
jects. Dual screening, utilising both HbA1c and FPG, may provide a more accurate method for
predicting cardiometabolic events. Earlier diagnosis could enable earlier targeted interventions
or therapies, thus attenuating development of type 2 diabetes and associated cardiovascular
complications.
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